# M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

Source: https://onco.cc/trials/nct06421935/  
OnCo record `nct06421935` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests a PARP inhibitor; the registry reports that it is active not recruiting.

## Summary

The registry lists NCT06421935 as active not recruiting, last updated 2026-09-09. Enrolment is 60 actual participants. Interventions: M9466, Tuvusertib, Abiraterone acetate, Prednisone/Prednisolone. Primary measures include Module 1 Part A1 and Part A2: Number of Participants With Treatment-Emergent Adverse Events (TEAE), and Treatment-related AEs (TRAEs); Module 1 Part A1 and Part A2: Number of Participants with Dose Limiting Toxicity (DLT)-like events. No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-10-06
- Registry id: NCT06421935
- Phase: 1
- Setting: An Open Label, Multicenter, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of the PARP1 Inhibitor M9466 Alone or in Combination in Participants With Advanced Solid Tumors
- Sponsor: EMD Serono Research & Development Institute, Inc.
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT06421935: https://clinicaltrials.gov/study/NCT06421935

## Connected records

- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [HRS-1167](https://onco.cc/drugs/hrs-1167/)

---
JSON: https://onco.cc/api/v1/entities/nct06421935.json